molgramostim inhaled (MOLBREEVI)

Savara is awaiting an FDA decision on molgramostim inhaled (brand name MOLBREEVI), a recombinant form of granulocyte-macrophage colony-stimulating factor (GM-CSF) delivered by nebulizer for autoimmune pulmonary alveolar proteinosis (aPAP). aPAP is a rare lung disease where patients make antibodies that neutralize their own GM-CSF, a signaling protein the lungs need to keep themselves clean. Without working GM-CSF, the immune cells in the lung (alveolar macrophages) cannot clear the surfactant that coats the air sacs, and patients slowly suffocate on accumulated lung fluid. The BLA is under FDA Priority Review with a PDUFA action date of November 22, 2026, extended three months from the original August 22, 2026 target after FDA determined that Savara's responses to information requests constituted a major amendment [7]. The Phase 3 IMPALA-2 trial (NCT04544293, n=164) published in the New England Journal of Medicine in 2025 showed improvement in DLCO (diffusing capacity for carbon monoxide), a standard lung function test that measures how efficiently inhaled test gas crosses into the bloodstream, a direct readout of the gas exchange surface destroyed by surfactant buildup [1][3]. There is no approved drug for aPAP today. Current standard of care is whole lung lavage, a hospitalization where surgeons physically wash the patient's lungs out under general anesthesia. A successful approval would create a first-in-disease commercial category for Savara, a single-asset biotech whose entire valuation hinges on this outcome.

Molgramostim inhaled (MOLBREEVI) is a novel investigational drug under FDA review. The BLA has been accepted under Priority Review, with the PDUFA action date currently set at November 22, 2026 [7]. The original PDUFA was August 22, 2026; in April 2026 FDA extended review by three months after classifying Savara's responses to FDA information requests as a major amendment to the BLA. FDA cited no safety, efficacy, or manufacturing concerns in announcing the extension [7]. The drug holds Orphan Drug, Fast Track, Breakthrough Therapy, and Priority Review designations from the FDA. Savara has been pursuing aPAP since acquiring the asset from Serendex in 2017, and IMPALA-2 is the company's second Phase 3 attempt after the first IMPALA missed its primary endpoint. Orphan-eligible disease economics apply given aPAP affects roughly 7 to 10 adults per million. The key data published in NEJM in 2025 supports the regulatory submission [1]. A separate open-label pediatric Phase 3 (NCT06431776, n=5) is recruiting to support label extension into children [4]. Savara has no other clinical-stage assets, so the PDUFA outcome is binary for the company's commercial future. Beyond aPAP, an earlier-stage open-label pilot tested molgramostim in pulmonary nontuberculous mycobacterial infection (OPTIMA, published 2024), but Savara has not advanced that indication into registrational work [5]. The drug is delivered through an eFlow nebulizer, a portable mesh device patients use at home. If approved, this would be the first pharmacological treatment for aPAP, replacing or delaying the need for repeated whole lung lavage procedures.

GM-CSF is a small protein the body uses to tell macrophages, the cleanup cells of the immune system, to mature and do their job. In the lung, alveolar macrophages have one main task: vacuum up surfactant, the soapy film that keeps air sacs from collapsing on every exhale. Surfactant is constantly being produced and constantly being cleared. In aPAP, patients develop autoantibodies that bind and neutralize their own GM-CSF before it can signal [1]. The macrophages never get the activation signal, surfactant accumulates, the air sacs fill with proteinaceous goo, and gas exchange falls off. Patients experience progressive shortness of breath that worsens over years. The mechanism is genetically and biologically airtight: people with inherited mutations in the GM-CSF receptor (CSF2RA/CSF2RB) develop a hereditary form of PAP that looks clinically identical, confirming that loss of GM-CSF signaling is sufficient to cause the disease [1]. Molgramostim is recombinant human GM-CSF (functionally similar to sargramostim, the approved injectable used to boost white blood cell counts after chemotherapy, but produced in a different expression system). Delivering it directly into the airways floods the lung with enough GM-CSF to overwhelm the neutralizing antibodies locally, restore macrophage function, and allow surfactant clearance. The Phase 1 pharmacokinetic study confirmed minimal systemic exposure with inhaled delivery, which is exactly what you want to avoid the leukocytosis and bone pain seen with systemic GM-CSF dosing [2].

IMPALA-2 (NCT04544293) is a Phase 3, randomized, double-blind, placebo-controlled trial that enrolled 164 adults with aPAP [3]. Patients were randomized to inhaled molgramostim 300 µg daily versus matched placebo nebulizer for 48 weeks, with the primary endpoint at Week 24: change from baseline in percent-predicted DLCO adjusted for hemoglobin [3]. DLCO is the correct endpoint pick here. It measures how efficiently a test gas (carbon monoxide) crosses from inhaled air into the bloodstream, which is exactly the physiological function destroyed by surfactant buildup in the air sacs. Entry criteria required confirmed diagnosis (GM-CSF autoantibody positive) and DLCO between 30% and 75% predicted, capturing the moderate disease band where benefit is most measurable and patients still have functional reserve to gain. Results: molgramostim improved percent-predicted DLCO by 9.8 points versus 3.8 points for placebo at Week 24 (treatment difference 6.0 points, P<0.001), with the gap widening at Week 48 (11.6 vs. 4.7 points, difference 6.9 points, P<0.001) [1]. The Week 48 effect size approaches the 10-point minimal clinically meaningful difference reported for DLCO in pulmonary fibrosis, supporting clinical relevance beyond statistical significance. The first IMPALA trial used the same DLCO endpoint and missed it on the primary analysis (though numerically favored molgramostim), so the design team tightened entry criteria and dosing schedule for IMPALA-2. The NEJM 2025 publication reports a positive primary endpoint result supporting Savara's BLA submission [1]. A systematic review and meta-analysis of inhaled GM-CSF in aPAP also confirmed directional consistency of benefit across multiple programs [6]. Enrollment has completed and the trial is active-not-recruiting in long-term follow-up. The pediatric study (NCT06431776) is an open-label single-arm pilot (n=5) rather than a randomized trial, designed to generate pediatric safety/PK data to support a label extension into children [4].

Our model puts this drug's chances of eventual approval at 26%. That estimate starts from the historical approval rate for Phase 3 drugs in this area (about 55%), then adjusts based on ten facts about the trial and sponsor. The biggest drags on the estimate are smaller-than-typical enrollment, a thin or weak sponsor approval record, and weak or limited earlier-phase results; a non-randomized trial design works in its favor. The remaining factors land near average for this stage and do not move the number much either way.

The dominant risk now is not approval, it is commercial uptake. aPAP affects roughly 7 to 10 cases per million adults in the US, putting the addressable population in the low thousands. Pricing in ultra-rare disease typically lands in the $200K to $500K range annually, but payer pushback gets harder when whole lung lavage exists as a procedural alternative, even if it is invasive and many patients need it repeated every one to two years. Differentiating outcomes versus lavage on patient-reported quality of life and exacerbation frequency will drive uptake more than DLCO numbers alone. Efficacy risk going into the PDUFA is low given the published Phase 3 (6.0-point treatment difference at Week 24 widening to 6.9 points at Week 48), but durability past 48 weeks remains an open question and will need real-world data to support payer coverage. Safety risk is also limited: pharmacokinetic data confirm minimal systemic GM-CSF exposure with the inhaled formulation [2], avoiding the leukocytosis and bone pain seen with sargramostim injections. Remaining safety watch items are local airway irritation and a theoretical concern about sustained macrophage activation in the airway, neither flagged at problematic rates in the trial data published so far [1]. Execution risk concentrates in Savara itself: it is a single-asset biotech with no commercial infrastructure, so launch depends on either building a small specialty sales force or partnering. Cash runway and partnering signals through 2026 are worth tracking closely, with the 2025 10-K disclosure as the primary public datapoint [8].

Worth watching, and worth a position view if you cover ultra-rare respiratory. The November 22, 2026 PDUFA is the revised action date, not the original. The FDA extended review by three months in April 2026 after classifying Savara's responses to FDA information requests as a major amendment to the BLA; FDA cited no safety, efficacy, or manufacturing concerns. That is a procedural delay rather than a red flag, but it is not a clean review and an investor should track it as such. Signals to track between now and PDUFA: any FDA advisory committee notification (none scheduled as of public disclosures), further communications or amendment activity on the BLA, updates in Savara 8-K filings, and any partnership or M&A activity around the company. Savara has no commercial infrastructure, so the company has two paths after approval: build a small specialty sales force or get acquired. Both happen often in ultra-rare disease where launch economics favor focused operators. The acquisition multiple math is generous when approval is essentially de-risked and the patient population is small but premium-priced. The pediatric trial readout (NCT06431776) is the next clinical catalyst beyond approval itself and would expand the label into children [4]. Specific check-in date: October 2026, ahead of any pre-PDUFA disclosure (a complete response letter is uncommon when the Phase 3 was positive and published in NEJM and FDA has flagged no concerns in the extension notice, but the tail risk is never zero) [1][7].